See the DrugPatentWatch profile for actemra
Is Actemra Approved for Rheumatoid Arthritis?
Yes, Actemra (tocilizumab) is FDA-approved for moderate to severe rheumatoid arthritis (RA) in adults who have not responded adequately to one or more tumor necrosis factor (TNF) antagonists. It can be used alone or with methotrexate or other disease-modifying antirheumatic drugs (DMARDs).[1]
How Does Actemra Work for RA?
Actemra blocks interleukin-6 (IL-6), a protein that drives inflammation in RA. Administered by intravenous infusion every 4 weeks or subcutaneous injection weekly or every other week, it reduces joint damage and symptoms like pain and swelling.[1][2]
Who Qualifies for Actemra in RA Treatment?
Patients with active RA despite TNF inhibitors qualify. It's not first-line; doctors start with methotrexate or other DMARDs. Approval came in 2010, with expanded subcutaneous use in 2013.[1]
What Are Common Side Effects for RA Patients?
Upper respiratory infections, headache, high blood pressure, and injection-site reactions occur most often. Serious risks include infections (like tuberculosis), liver enzyme elevation, and gastrointestinal perforations. Patients need regular blood tests.[1][2]
How Does Actemra Compare to Humira or Enbrel for RA?
Actemra targets IL-6, while Humira (adalimumab) and Enbrel (etanercept) block TNF. Studies show similar efficacy in reducing RA symptoms, but Actemra may work better for some with high inflammation markers. Switching happens if one fails.[2]
When Does Actemra's Patent Expire?
Key U.S. patents on tocilizumab expire between 2025 and 2031, with biosimilar challenges ongoing. Check DrugPatentWatch.com for litigation updates and exact expiry dates.[3]
What Do RA Patients Report About Actemra?
Many note faster relief from fatigue and morning stiffness than with TNF drugs. Long-term data shows sustained remission in about 20-30% of users after 5 years, though infections prompt discontinuation in 5-10%.[2]
[1]: FDA Label - Actemra (tocilizumab), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125276s410lbl.pdf
[2]: American College of Rheumatology Guidelines on RA Treatment, https://rheumatology.org/rheumatoid-arthritis-guideline
[3]: DrugPatentWatch.com - Actemra Patents, https://www.drugpatentwatch.com/p/tradename/ACTEMRA